Yahoo
NYSE - Nasdaq Real Time Price USD

Abbott Laboratories (ABT)

86.41 -0.76 (-0.88%)
As of 12:28:59 PM EDT. Market Open.
Trade ABT on Coinbase
Chart Range Bar
Loading chart for ABT

News headlines Abbott Laboratories is facing challenges with its stock trading at 52-week lowsdespite generating $44.3 billionin annual revenue. Recent FDA approvals for its Ultreon 3.0 software may offer growth opportunities, but analysts express caution due to declining profitability and uncertain market conditions.

Abbott Laboratories is facing challenges with its stock trading at 52-week lowsdespite generating $44.3 billionin annual revenue. Recent FDA approvals for its Ultreon 3.0 software may offer growth opportunities, but analysts express caution due to declining profitability and uncertain market conditions.

Updated 6m ago · Powered by Yahoo Scout
  • Previous Close 87.17
  • Open 87.55
  • Bid 86.70 x 20000
  • Ask 86.73 x 20000
  • Day's Range 86.35 - 87.69
  • 52 Week Range 86.16 - 139.06
  • Volume 3,313,598
  • Avg. Volume 11,713,171
  • Market Cap (intraday) 150.501B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) 24.20
  • EPS (TTM) 3.57
  • Earnings Date (est.) Jul 16, 2026
  • Forward Dividend & Yield 2.52 (2.89%)
  • Ex-Dividend Date Apr 15, 2026
  • 1y Target Est 118.64

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

www.abbott.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview: ABT

Trailing total returns as of 5/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABT
30.25%
S&P 500 (^GSPC)
7.25%

1-Year Return

ABT
33.74%
S&P 500 (^GSPC)
30.94%

3-Year Return

ABT
17.53%
S&P 500 (^GSPC)
77.49%

5-Year Return

ABT
20.10%
S&P 500 (^GSPC)
74.73%

Earnings Trends: ABT

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 11.16B
Earnings 2.02B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2B
4B
6B
8B
10B

Analyst Insights: ABT

View More

Analyst Price Targets

92.00
118.64 Average
86.40 Current
143.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/27/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 131 -> 131

Statistics: ABT

View More

Valuation Measures

Annual
As of 5/4/2026
  • Market Cap

    152.48B

  • Enterprise Value

    179.23B

  • Trailing P/E

    24.52

  • Forward P/E

    15.97

  • PEG Ratio (5yr expected)

    1.30

  • Price/Sales (ttm)

    3.39

  • Price/Book (mrq)

    2.93

  • Enterprise Value/Revenue

    3.97

  • Enterprise Value/EBITDA

    15.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.90%

  • Return on Assets (ttm)

    5.59%

  • Return on Equity (ttm)

    12.33%

  • Revenue (ttm)

    45.13B

  • Net Income Avi to Common (ttm)

    6.25B

  • Diluted EPS (ttm)

    3.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.3B

  • Total Debt/Equity (mrq)

    64.77%

  • Levered Free Cash Flow (ttm)

    6.34B

Compare To: ABT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ABT

Fair Value

86.40 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: ABT

View More
  • Daily – Vickers Top Buyers & Sellers for 04/29/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Adds cancer diagnostics with acquisition

    Abbott Laboratories is a diversified healthcare company that develops, manufactures and markets a wide range of medical products and services. Its main product lines are nutritionals for adults and infants, diagnostic systems, vascular implants, cardiac rhythm management products, and diabetes care products.

    Rating
    Price Target
  • The major stock indices are lower at midday on Monday. The war with Iran is

    The major stock indices are lower at midday on Monday. The war with Iran is now in its eighth week, and good news concerning the opening of the Strait of Hormuz last week faded over the weekend, with the Strait now closed yet again. The current ceasefire ends on Wednesday of this week. Crude oil is currently at about $87 per barrel, up 6% today but down sharply from an intraday high of $118 hit on April 7. Aside from war developments, a heavy earnings flow continues. The yield on the 10-year note is at 4.27%, and the VIX volatility index is at 19.

  • Abbott Earnings: Weakness in US Markets Softened by Strength in Foreign Markets

    Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: